- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 19.12.25 | GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst | 7 | Benzinga.com | ||
| 18.12.25 | CAMP4 Therapeutics Teams With GSK On ASO Drug Candidates | 409 | AFX News | LONDON (dpa-AFX) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide... ► Artikel lesen | |
| 18.12.25 | CAMP4 Therapeutics prices $30 million common stock offering | 4 | Investing.com | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | GSK pays $17.5M to pitch its tent with CAMP4 in regulatory RNA deal | 12 | FierceBiotech | ||
| 18.12.25 | CAMP4 Therapeutics: CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock | 237 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 18.12.25 | CAMP4 Therapeutics: CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries | 264 | GlobeNewswire (Europe) | Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront... ► Artikel lesen | |
| 18.12.25 | Camp4 Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.12.25 | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 11.12.25 | Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock | 1 | Investing.com | ||
| 14.11.25 | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 07.11.25 | Camp4 Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 07.11.25 | Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates | 12 | FierceBiotech | ||
| 02.10.25 | Cantor Fitzgerald initiates CAMP4 Therapeutics stock with Overweight rating | 1 | Investing.com | ||
| 02.10.25 | Cantor Fitzgerald startet Coverage für CAMP4 Therapeutics mit "Overweight" | 3 | Investing.com Deutsch | ||
| 01.10.25 | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10.25 | CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy | 1 | Investing.com | ||
| 01.10.25 | CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 | 162 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 16.09.25 | JPMorgan downgrades CAMP4 Therapeutics stock to Neutral on long timeline | 1 | Investing.com | ||
| 15.09.25 | CAMP4 Therapeutics stock price target lowered to $12 at Piper Sandler | 1 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | QIAGEN: Wochengewinner im DAX - Analyse der KW 4 | ||
| PRAXIS PRECISION MEDICINES | 314,30 | -0,12 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,03 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,58 | +0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARVINAS | 13,380 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab |
Das Unternehmen CAMP4 THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,40 % bei einem Aktienkurs von 3,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.